Premium
Mortality risk with sulphonylureas compared to metformin
Author(s) -
Holden S. E.,
Currie C. J.
Publication year - 2014
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12280
Subject(s) - metformin , medicine , type 2 diabetes , diabetes mellitus , harm , pharmacology , endocrinology , intensive care medicine , psychology , social psychology
Current clinical guidelines in the USA and the UK recommend first‐line glucose‐lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.